Tingfang Wang

Dr. Tingfang Wang


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2023 in Journal of Controlled Release
Verified
Journal Article
Closed access
JLJun Liao
Jun Liao
LFLi Fan
Li Fan
YLYi Li
Yi Li
QXQing-Qiang Xu
Qing-Qiang Xu
LXLi-Yan Xiong
Li-Yan Xiong
YLYing Lu
Ying Lu

15 March 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
YLYi Li
Yi Li
JLJun Liao
Jun Liao
LXLiyan Xiong
Liyan Xiong
ZXZhicheng Xiao
Zhicheng Xiao
FYFei Ye
Fei Ye
YLYing Lu
Ying Lu

12 September 2023 in Advanced Science
Verified
Journal Article
Open access
ZXZhicheng Xiao
Zhicheng Xiao
YLYi Li
Yi Li
LXLiyan Xiong
Liyan Xiong
JLJun Liao
Jun Liao
YGYijun Gao
Yijun Gao
Zhe-Sheng ChenZhe-Sheng Chen
Zhe-Sheng Chen
Atherosclerosis, the leading cause of death worldwide, is responsible for ≈17.6 million deaths globally each year. Most therapeutic drugs for atherosclerosis have low delivery efficiencies and significant side effects, and this has hampered the development of effective treatment strategies. Diversified nanomaterials can improve drug properties and are considered to be key for the development of improved treatment strategies for atherosclerosis. The pathological mechanisms underlying atherosclerosis is summarized, rationally designed nanoparticle‐mediated therapeutic strategies, and potential future therapeutic targets for nanodelivery. The content of this study reveals the potential and challenges of nanoparticle use for the treatment of atherosclerosis and highlights new effective design ideas.

16 August 2016 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
DYDebin Yang
Debin Yang
TWTingfang Wang
Tingfang Wang
ZSZhigui Su
Zhigui Su
LXLingjing Xue
Lingjing Xue
RMRan Mo
Ran Mo
CZCan Zhang
Can Zhang

27 November 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
SYShiyu Yang
Shiyu Yang
HCHeming Chen
Heming Chen
WSWei Su
Wei Su
YLYunchun Luo
Yunchun Luo
JLJun Liao
Jun Liao
TWTingfang Wang
Tingfang Wang
Ischemia-reperfusion (I/R) injury refers to a new injury caused by reperfusion after the restoration of ischemic tissue or organ blood supply. Salvianic acid A (danshensu) is a primary active ingredient extracted from Salvia miltiorrhiza. It has a protective function against I/R injury in the cardiovascular system, brain, liver, kidney, gastrointestinal tract, and other organs. This article reviews evidence of the protective effects of Salvianic acid A and its potential mechanisms of action in organ I/R injury protection. The aim of this review is to investigate the role of Salvianic acid A in the treatment of I/R injury, providing a reference resource that could facilitate subsequent studies.

19 November 2022 in Bioorganic Chemistry
Verified
Journal Article
Closed access
YLYi Li
Yi Li
YLYunchun Luo
Yunchun Luo
JWJing Wang
Jing Wang
HSHao Shi
Hao Shi
JLJun Liao
Jun Liao
TWTingfang Wang
Tingfang Wang